Eli Lilly will spend $5.3 billion to boost manufacturing capacity for its anti-obesity drug Zepbound and cousin diabetes drug Mounjaro.
Wall Street Journal
Eli Lilly will spend $5.3 billion to boost manufacturing capacity for its anti-obesity drug Zepbound and cousin diabetes drug Mounjaro.